Jazz Pharmaceuticals

News

Jazz and Lilly cancer drugs cleared for use by NHS

Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Sand picture of balloons as brains, flown by man and child

Jazz gets FDA okay for Chimerix brain cancer drug

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.

News

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.

News

Dyvyzat box, bottle, and oral delivery mechanism.

Italfarmaco closes on EU okay for Duchenne drug

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

Jazz and Lilly cancer drugs cleared for use by NHS

Servier snaps up cancer biotech Day One in $2.5bn deal

Jazz, Roche combo cleared by FDA for lung cancer

Jazz gets FDA okay for Chimerix brain cancer drug

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Italfarmaco closes on EU okay for Duchenne drug

Reports: Makary out, Diamantas in as FDA commissioner

Discover a new era of healthcare panel engagement: Grounded ...

Jazz Pharmaceuticals

Editor's Picks